Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Naam

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Clinical Genitourinary Cancer|September 29, 2012
Thyroid dysfunction in patients treated with sunitinib or sorafenibJulia Clemons, Dexiang Gao, Mary Naam, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|March 8, 2013
Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinomaKathryn Breaker, Mary Naam, Francisco G La Rosa, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Clinical Genitourinary Cancer|September 29, 2012
Thyroid dysfunction in patients treated with sunitinib or sorafenibJulia Clemons, Dexiang Gao, Mary Naam, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|March 8, 2013
Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinomaKathryn Breaker, Mary Naam, Francisco G La Rosa, et al.
Pageof 1